Firms
Arboretum Ventures is a healthcare venture capital firm that backs early-stage companies and helps entrepreneurs build and grow their businesses. Its investment, finance and advisory teams provide capital, operating experience and healthcare expertise to companies developing medical technologies and care solutions.
Founded —
Type Venture capital Funds0 No funds on record yet.
Team$1M $100K – $5M Durham, North Carolina $1M $100K – $5M Hong Kong $1M $100K – $5M San Francisco Bay Area $1M $100K – $5M Singapore $1M $100K – $5M United States $10M $10M – $15M — — – —
SHOW MORE
Investments$20M 2026-02-18 Pharaoh Neuro Arboretum Ventures , Hatteras Venture Partners , Laerdal Million Lives Fund , IAG Capital Partners $18M 2024-01-24 Motif Neurotech Arboretum Ventures , Dolby Family Ventures , KdT Ventures , Satori Neuro , re.Mind Capital , Max Hodak , Divergent Capital , TMC Innovation , PsyMed Ventures , Empath Ventures , Capital Factory
SHOW MORE
team@apexlogos.ai · 4 hours ago
October 7, 2026 identity correction: imported roles 552, 564, 565 and 566 belong to Arbor Ventures, a separate fintech manager, per Arbor’s official team page. Their existing personal-investor attribution links are transferred to correct Arbor roles before native removal of the erroneous Arboretum affiliations. The people and financing records are preserved. Four other historical imported names require separate identity review before further corrections. SHOW MORE
team@apexlogos.ai · 4 hours ago
Team reviewed October 7, 2026: the firm publishes 24 unique people, comprising 15 investment, finance and administrative staff and nine advisers. Nicole Vitullo also appears in adviser biographies and is recorded once as venture partner. Arboretum associate James Kim is kept separate from the existing Jona engineer of the same name. Jeff Terrell’s current title is managing partner on the firm’s own page. Fund VI’s $268 million 2023 close precedes the October 6, 2023 search window; no verified recent Fund VII close has been added. The existing Pharaoh Neuro 2026 Series A lead participation is retained. SHOW MORE